Media Contacts

For more information contact our media team:

Stacy Sevcik
+1 314 529 3062
Send Email >

Next Event

  • e-Health Research International Congress 2016

    Paris, France
    Oct11 – 12, 2016

    Learn More

Kantar Health thought leaders are available to comment on a variety of healthcare- and pharma-industry-related topics. In addition, our proprietary data is available for media use, including patient population sizes, treatment rates and patient-reported behaviors and attitudes.

Welcome to the Kantar Health News Room RSS Feed News

Delivering the most current and unique insights on healthcare trends and news about Kantar Health.
  • Kantar Health Data Show Zytiga Is Most Used First-Line Treatment in Prostate Cancer

    Apr 23, 2013
    Zytiga® (abiraterone acetate, Janssen) is now the most used first-line treatment in Stage IV prostate cancer patients in the United States, according to new findings from CancerMPact® Monthly Drugs and Regimens.
    Continue Reading | Share
  • Kantar Health Launches CancerMPact Future Trends and Insights

    Apr 16, 2013
    Kantar Health today announced the availability of CancerMPact® Future Trends and Insights, a new solution that explores potential changes in oncology treatment practices in the United States, Western Europe and Japan.
    Continue Reading | Share
  • Kantar Health to Present at Pharma China Forum

    Apr 12, 2013
    Kantar Health, a leading global healthcare advisory firm, today announced that it will present at the Pharma China Forum 2013 in Shanghai on April 25, 2013.
    Continue Reading | Share
  • Hypertension Awareness Remains Low with Consumers, According to Recently Released Data from Kantar Health

    Apr 4, 2013
    Despite the rising prevalence of hypertension worldwide, the number of patients diagnosed with the disease remains low when compared with estimated prevalence, according to new findings from Kantar Health’s National Health and Wellness Survey (NHWS).
    Continue Reading | Share
  • MS Patients on Oral Therapies Are More Optimistic About Their Disease, According to Kantar Health Survey

    Apr 3, 2013
    Multiple sclerosis patients who are taking oral disease-modifying drugs (DMD) are more optimistic about their future expectations for their disease than patients who are taking non-oral DMDs.
    Continue Reading | Share
  • Kantar Health to Present at Pharma China Seminar

    Apr 2, 2013
    Kantar Health, a leading global healthcare advisory firm, will present at the Pharma China Seminar 2013 in Princeton, N.J., on April 16, 2013.
    Continue Reading | Share
  • Pfizer, MSD Rank Highest on Academic Marketing in China, According to Kantar Health Research

    Mar 26, 2013
    Physicians in China ranked Pfizer and MSD highest among multinational pharmaceutical companies operating in that country in terms of academic marketing, according to new research conducted by Kantar Health and DXY.cn.
    Continue Reading | Share
  • Kantar Health to Present at PMRG Annual National Conference

    Mar 5, 2013
    Kantar Health today announced that its global compliance director, Jessica Santos, Ph.D., will present at the Pharmaceutical Marketing Research Group (PMRG) Annual National Conference on March 12, 2013, in National Harbor, Maryland.
    Continue Reading | Share
  • Kantar Health and Roche Jointly Develop Health Economics Model with Egypt’s Largest Payer

    Feb 20, 2013
    Kantar Health recently partnered with Roche Egypt to help bring the latest thinking in health economics and cost-effectiveness analysis to the country’s largest payer, the Health Insurance Organization (HIO).
    Continue Reading | Share
  • Kantar Health Research Delivers New Insights into Biosimilar Opportunities in China

    Feb 13, 2013
    Kantar Health, a leading global advisory and marketing research company, today released new, syndicated research analyzing the growth potential and challenges for biosimilars in China.
    Continue Reading | Share
Page